Glenmark Steps Closer To First NCE With Positive Phase II Data For Crofelemer; Gears Up For Larger Trials
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Years of racing to put an original compound into the market looks set to be one step closer for India's Glenmark Pharmaceuticals as the company announced successful completion of Phase II multi-center clinical trials in India for its first-in-class anti-diarrheal agent crofelemer
You may also be interested in...
Following U.S. FDA Approval, Glenmark Plans Multi-Geography Launches For Crofelemer
India’s Glenmark has sped up its regulatory filings in a large set of countries, enthused by the prospects of filling unmet needs for HIV treatment regimens.
Glenmark Plays Down Napo’s Deal Termination For Crofelemer; Expects Launch In 12-18 Months
India’s Glenmark will go ahead with filing crofelemer NDA despite conflict with its partner Napo Pharmaceuticals, which cancelled the development partnership
MNC Exodus Continues As Lilly India Head Sandeep Gupta Leaves For Glenmark Pharma
Following a recent trend in emerging markets, Eli Lilly’s India Head shifts to Glenmark